Skip to main content
Fig. 8 | Cancer Cell International

Fig. 8

From: Attenuated expression of SNF5 facilitates progression of bladder cancer via STAT3 activation

Fig. 8

Putative chemotherapeutic responses in BC. A The estimated IC50 for FDA-approved drugs, including cisplatin, gemcitabine, doxorubicin and mitomycin, in BC patients in TCGA. B The estimated IC50 of AKT inhibitor VIII, AZD-0530 and Gefitinib in BC patients and C Validation of findings in drug resistance assays. D Drug resistance assay was performed to determine the viabilities of the indicated cells exposed to cisplatin with or without GSK126, an EZH2 inhibitor. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001

Back to article page